Abstracts tagged "Interferons and systemic lupus erythematosus (SLE)"

Abstract Number: 2271 • 2012 ACR/ARHP Annual Meeting
Variation of Interferon-Alpha Production in Healthy Individuals and Association with Autoimmune Susceptibility Genes
Olof Berggren¹, Andrei Alexsson², Gunnar V. Alm³, Ann-Christine Syvänen⁴, Lars Rönnblom² and Maija-Leena Eloranta², ¹Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ²Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, ³Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden, ⁴Department of Medical Sciences, Molecular Medicine, Uppsala University, Uppsala, Sweden
Background/Purpose: Many autoimmune diseases, e.g. systemic lupus erythematosus (SLE), have an activated type I interferon (IFN) system and about 40 SLE susceptibility loci, many within…
Abstract Number: 1809 • 2012 ACR/ARHP Annual Meeting
Serum IFNα Activity in Systemic Lupus Erythematosus Drops in Response to Immunosuppressive Therapy Only When There Is Concurrent Clinical Response
Elzbieta E. Jacek¹, Elena Gkrouzman¹, Mikhail Olferiev¹, Nancy Pan², Roland Duculan³, Kyriakos A. Kirou¹ and Mary K. Crow⁴, ¹Hospital for Special Surgery, New York, NY, ²Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ³Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, Hospital for Special Surgery, New York, NY, ⁴Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: The type I interferon (IFN-I) signature, describing expression in PBMC of a large set of gene transcripts induced by IFN-I, and increased serum IFNα…
Abstract Number: 1456 • 2012 ACR/ARHP Annual Meeting
A Tolerogenic Peptide Down-Regulates the Expression of Interferon-a in Murine and Human Systemic Lupus Erythematosus
Zev M. Sthoeger¹, Heidy Zinger², Amir Sharabi², Ilan Asher¹ and Edna Mozes², ¹Department of Medicine, Kaplan Hospital, Rehovot, Israel, ²The Weizmann institute of Science, Rehovot, Israel
Background/Purpose: The tolerogenic peptide, designated hCDR1, was shown to ameliorate manifestations of systemic lupus erythematosus (SLE) via down-regulation of pro-inflammatory cytokines, up-regulation of immunosuppressive cytokines…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].